TN, USA
André Tichelli
University Hospital Basel
Basel, Switzerland
This edition first published 2021 © 2021 John Wiley & Sons Ltd
Edition History John Wiley & Sons Ltd (1e, 2013)
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Bipin N. Savani and André Tichelli to be identified as the authors of the editorial material in this work has been asserted in accordance with law.
Registered Offices John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial Office 9600 Garsington Road, Oxford, OX4 2DQ, UK
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data
Names: Savani, Bipin N., editor. | Tichelli, André, editor.
Title: Blood and marrow transplantation long term management : survivorship after transplant / edited by Bipin N Savani, André Tichelli.
Description: Second edition. | Hoboken, NJ : Wiley‐Blackwell, 2021. | Includes bibliographical references and index.
Identifiers: LCCN 2020053132 (print) | LCCN 2020053133 (ebook) | ISBN 9781119612698 (hardback) | ISBN 9781119612742 (adobe pdf) | ISBN 9781119612735 (epub)
Subjects: MESH: Hematopoietic Stem Cell Transplantation–adverse effects | Long Term Adverse Effects–prevention & control | Disease‐Free Survival | Survivors
Classification: LCC RD123.5 (print) | LCC RD123.5 (ebook) | NLM WH 380 | DDC 617.4/410592–dc23
LC record available at https://lccn.loc.gov/2020053132 LC ebook record available at https://lccn.loc.gov/2020053133
Cover Design: Wiley
Cover Image: Bipin N. Savani and André Tichelle
Foreword to the Second Edition
by Professor John Barrett
Since 2013 when the publication of the first edition of Savani’s Blood and Marrow Transplantation Long Term Management: Prevention and Complications the accelerated pace of stem cell transplant activity worldwide since the beginning of this century, together with the continuing trend to reduced early mortality from the procedure has translated into an almost exponential expansion in the number of long term survivors which must now number well beyond half a million individuals surviving more than five years. More than ever, to serve our patients we need this authoritative guide for the management of our long‐term survivors as well as a comprehensive and contemporaneous account of the causative factors of long‐term complications that can inform us of better ways to do stem cell transplants.
What have we learned in the last few years? Chronic graft‐versus‐host disease (C‐GVHD) is increasingly recognized as a cause of late effects not hitherto ascribed to this common post‐transplant event. It is now clear that human papilloma virus (HPV) contributes to a significant proportion of the second malignancies which relentlessly increase over time after transplant. Understanding the impact of these two risk factors is important in focusing efforts to avoid C‐GVHD, and by using post‐transplant HPV vaccination to reduce second malignancies. As observational studies of long‐term survivors accumulate, we are discovering new late effects extending beyond the familiar territories of GVHD and second tumors. In this newest edition, the section of organ‐specific late effects is greatly expanded. In particular delayed cardiovascular events are being defined, as well as a much clearer idea of the psychosocial and economic burden that long‐term survivors and their carers may experience. Finally, we are beginning to distinguish different trajectories of late effects due to particular transplant approaches. Over and above the well characterized differences on late outcomes after autologous versus allogeneic SCT databases are extensive enough to identify the impact of different and newer transplant approaches for example haplo‐identical donor transplants.
All this new information and increased competence in managing as well as preventing transplant late effects could not have been possible without a concerted effort from all the major transplant registries and societies to concentrate on the problem. This has led to the development of useful guidelines, dedicated multidisciplinary late effect clinics, and a gratifyingly broader knowledge base among transplant physicians and primary caregivers, which in turn leads to better patient management. The first
